Human Vaccines Market Size, Share, Growth, Trends, Consumption, Revenue, Company Analysis, Regional Insights and Forecast 2021-2030

The global human vaccine market size is expected to reach at US$ 84 billion by 2030 and is projected to grow at a CAGR of 9.1% from 2021 to 2030.

The extremely low risk of serious and fatal side effects, education and awareness through various governmental and non-profit organizations, growing preference for outsourcing of vaccine manufacturing are projected to drive the global human vaccine market during the forecast period.

Vaccination is the most effective measure for the prevention and control of a number of human and animal diseases. It has saved lives of millions of children, adults and animals, and provided them a better and healthier life.

Vaccination is an easier and less risky approach as compared to medicines to prevent a number of diseases from occurring in humans as well as animals. According to a study on the economic impact of routine childhood immunization in the U.S., every dollar spent on vaccination saves approximately US$ 5 in direct cost and nearly US$ 11 in additional cost to the society.

Growing Preference for Outsourcing of HPAPI Manufacturing to Drive Market

  • Earlier, pharmaceutical companies were skeptical in outsourcing manufacture of vaccines, and majority of the manufacturing was confined to captive or in-house. Major factor behind this was risk of patent infringement. However, as pharmaceutical companies started to expand geographical boundaries, they started experiencing shortage of vaccines.
  • Furthermore, increasing cost of drug development and commercialization added to the financial burden. With developing regulatory and legal framework, outsourcing proved to be the most optimal option for vaccine manufacturing.
  • Pharmaceutical companies can now focus on core business activities such as drug development and commercialization, while also take advantage of technical expertise at CMOs instead of investing in expensive vaccine manufacturing setup.

Conjugate Vaccines Segment to Dominate Market

  • Based on vaccine type, the global human vaccine market has been divided into conjugate, recombinant, inactivated, combination, attenuated, and others. The conjugate vaccines segment accounted for majority share of the global human vaccines market in 2018. The segment is projected to expand at an outstanding growth rate during the forecast period.
  • Prevnar, manufactured by Pfizer, Inc., is a conjugate vaccine. It generated revenue of US$ 6.2 Bn globally in 2015. This factor contributed the majority share of conjugate category in the human vaccine market. However, growing preference and large number of brands are driving the combination vaccines segment.

Meningococcal Vaccine to be Highly Lucrative Segment

  • In terms of product, the global human vaccine market has been classified into pneumococcal, influenza, hepatitis, HPV, meningococcal, rotavirus, measles and rubella, typhoid, combination, and others vaccines.
  • Rapidly increasing infectious diseases among people, large investment by the market players, and a number of premium products commercially available are propelling the global human vaccine market. Rich pipeline for vaccines is also likely to boost market growth post commercialization of the pipeline products. Low prevalence rate of others diseases is expected to lead to slow growth rate during the forecast period.
  • The ability to elicit greater and long-lasting immunity, facilitation of immunologic memory, and protection to infants are the major factors boosting meningococcal vaccine market growth.

North America to Dominate Global Market

  • In terms of region, the global human vaccine market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global human vaccine market in 2018, followed by Europe.
  • North America accounted for major share of the global human vaccine market in 2018. This is due to growing demand for vaccination among adults and children, increasing government efforts toward vaccination program, and most of the vaccines available in the U.S.
  • According to a study on the economic impact of routine childhood immunization in the U.S., every dollar spent on vaccination saves approximately US$ in direct cost and nearly US$ 11 in additional cost to the society.

Competitive Landscape

  • The global human vaccine market is fragmented in terms of number of players. Key players in the global market include AstraZeneca plc, Bavarian Nordic, Bharat Biotech, CSL Limited, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co, Inc., Mymetics, Novartis AG, Pfizer, Inc., Sanofi S.A., Shenzhen Kangtai Biological Products Co., Ltd., and Takeda Pharmaceutical Company Limited., among others.

The global human vaccine market has been segmented as follows:

By Vaccine Type

    • Conjugate
    • Recombinant
    • Inactivated
    • Combination
    • Attenuated
    • Others

By Product

    • Pneumococcal
    • Influenza
    • Hepatitis
    • HPV
    • Meningococcal
    • Rotavirus
    • Measles and Rubella
    • Typhoid
    • Combination
    • Others

By Distribution Channel

    • Hospital Pharmacies
    • Drugstores
    • Others

By Age Group

    • Pediatrics
    • Adolescents
    • Adults
    • Geriatrics

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific        
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Scope of Report

The Human vaccines market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.

The report provides size (in terms of volume and value) of Human vaccines market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

This report focuses on the global Human vaccines market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Human vaccines market development in United States, Europe and China.

It is pertinent to consider that in a volatile global economy, we haven’t just conducted Human vaccines market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.

In terms of production side, this report researches the Human vaccines capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.

In terms of consumption side, this report focuses on the consumption of Human vaccines by regions (countries) and application.

Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Human vaccines market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.

With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Human vaccines market companies.

Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Human vaccines market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.

The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.

Overall, this is an in-depth research report specifically for the Human vaccines industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.

Human vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Human vaccines market.

Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Human vaccines market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.

Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Human vaccines market. These factors have benefited the growth of the global market for Human vaccines. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.

New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Human vaccines. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).

In this study, the years considered to estimate the market size of Human vaccines are as follows:

  • History Year: 2017-2020
  • Base Year: 2020
  • Forecast Year 2021 to 2030

Reasons to Purchase this Report:

- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Market Size Estimation

Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).

The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.

Secondary Sources

Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.

Primary Sources

 In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.

The study objectives of this report are:

  • To analyze and study the global market capacity, production, value, consumption, status (2017-2020) and forecast (2021-2030);
  • Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Contents

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Human Vaccine Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Human Vaccine Market Analysis and Forecasts, 2018–2030

5. Key Insights

    5.1. Product Overview

    5.2. Key Industry Developments

    5.3. Emerging Trends in Human Vaccines Market

6. Global Human Vaccine Market Analysis and Forecasts, By Vaccine

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value  Forecast By Vaccine, 2018–2030

        6.3.1. Conjugate

        6.3.2. Recombinant

        6.3.3. Inactivated

        6.3.4. Combination

        6.3.5. Attenuated

        6.3.6. Others

    6.4. Market Attractiveness By Vaccine

7. Global Human Vaccine Market Analysis and Forecasts, By Product

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value  Forecast By Product, 2018–2030

        7.3.1. Pneumococcal

        7.3.2. Influenza

        7.3.3. Hepatitis

        7.3.4. HPV

        7.3.5. Meningococcal

        7.3.6. Rotavirus

        7.3.7. Measles and Rubella

        7.3.8. Typhoid

        7.3.9. Combination

        7.3.10. Others

    7.4. Market Attractiveness By Product

8. Global Human Vaccine Market Analysis and Forecasts, By Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value  Forecast By Distribution Channel, 2018–2030

        8.3.1. Hospital Pharmacies

        8.3.2. Drugstores

        8.3.3. Others

    8.4. Market Attractiveness By Distribution Channel

9. Global Human Vaccine Market Analysis and Forecasts, By Age Group

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value  Forecast By Age Group, 2018–2030

        9.3.1. Pediatrics

        9.3.2. Adolescents

        9.3.3. Adults

        9.3.4. Geriatrics

    9.4. Market Attractiveness By Age Group

10. Global Human Vaccine Market Analysis and Forecasts, By Region

    10.1. Key Findings

    10.2. Market Value  Forecast By Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness By Region

11. North America Human Vaccine Market Analysis and Forecast

    11.1. Introduction

    11.2. Market Value  Forecast By Vaccine, 2018–2030

        11.2.1. Conjugate

        11.2.2. Recombinant

        11.2.3. Inactivated

        11.2.4. Combination

        11.2.5. Attenuated

        11.2.6. Others

    11.3. Market Value  Forecast By Product, 2018–2030

        11.3.1. Pneumococcal

        11.3.2. Influenza

        11.3.3. Hepatitis

        11.3.4. HPV

        11.3.5. Meningococcal

        11.3.6. Rotavirus

        11.3.7. Measles and Rubella

        11.3.8. Typhoid

        11.3.9. Combination

        11.3.10. Others

    11.4. Market Value  Forecast By Distribution Channel, 2018–2030

        11.4.1. Hospital Pharmacies

        11.4.2. Drugstores

        11.4.3. Others

    11.5. Market Value  Forecast By Age Group, 2018–2030

        11.5.1. Pediatrics

        11.5.2. Adolescents

        11.5.3. Adults

        11.5.4. Geriatrics

    11.6. Market Value  Forecast By Country, 2018–2030

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Vaccine

        11.7.2. By Product

        11.7.3. By Distribution Channel

        11.7.4. By Age Group

        11.7.5. By Country

12. Europe Human Vaccine Market Analysis and Forecast

    12.1. Introduction

    12.2. Market Value  Forecast By Vaccine, 2018–2030

        12.2.1. Conjugate

        12.2.2. Recombinant

        12.2.3. Inactivated

        12.2.4. Combination

        12.2.5. Attenuated

        12.2.6. Others

    12.3. Market Value  Forecast By Product, 2018–2030

        12.3.1. Pneumococcal

        12.3.2. Influenza

        12.3.3. Hepatitis

        12.3.4. HPV

        12.3.5. Meningococcal

        12.3.6. Rotavirus

        12.3.7. Measles and Rubella

        12.3.8. Typhoid

        12.3.9. Combination

        12.3.10. Others

    12.4. Market Value  Forecast By Distribution Channel, 2018–2030

        12.4.1. Hospital Pharmacies

        12.4.2. Drugstores

        12.4.3. Others

    12.5. Market Value  Forecast By Age Group, 2018–2030

        12.5.1. Pediatrics

        12.5.2. Adolescents

        12.5.3. Adults

        12.5.4. Geriatrics

    12.6. Market Value  Forecast By Country, 2018–2030

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Vaccine

        12.7.2. By Product

        12.7.3. By Distribution Channel

        12.7.4. By Age Group

        12.7.5. By Country

13. Asia Pacific Human Vaccine Market Analysis and Forecast

    13.1. Introduction

    13.2. Market Value  Forecast By Vaccine, 2018–2030

        13.2.1. Conjugate

        13.2.2. Recombinant

        13.2.3. Inactivated

        13.2.4. Combination

        13.2.5. Attenuated

        13.2.6. Others

    13.3. Market Value  Forecast By Product, 2018–2030

        13.3.1. Pneumococcal

        13.3.2. Influenza

        13.3.3. Hepatitis

        13.3.4. HPV

        13.3.5. Meningococcal

        13.3.6. Rotavirus

        13.3.7. Measles and Rubella

        13.3.8. Typhoid

        13.3.9. Combination

        13.3.10. Others

    13.4. Market Value  Forecast By Distribution Channel, 2018–2030

        13.4.1. Hospital Pharmacies

        13.4.2. Drugstores

        13.4.3. Others

    13.5. Market Value  Forecast By Age Group, 2018–2030

        13.5.1. Pediatrics

        13.5.2. Adolescents

        13.5.3. Adults

        13.5.4. Geriatrics

    13.6. Market Value  Forecast By Country, 2018–2030

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis

        13.7.1. By Vaccine

        13.7.2. By Product

        13.7.3. By Distribution Channel

        13.7.4. By Age Group

        13.7.5. By Country

14. Latin America Human Vaccine Market Analysis and Forecast

    14.1. Introduction

    14.2. Market Value  Forecast By Vaccine, 2018–2030

        14.2.1. Conjugate

        14.2.2. Recombinant

        14.2.3. Inactivated

        14.2.4. Combination

        14.2.5. Attenuated

        14.2.6. Others

    14.3. Market Value  Forecast By Product, 2018–2030

        14.3.1. Pneumococcal

        14.3.2. Influenza

        14.3.3. Hepatitis

        14.3.4. HPV

        14.3.5. Meningococcal

        14.3.6. Rotavirus

        14.3.7. Measles and Rubella

        14.3.8. Typhoid

        14.3.9. Combination

        14.3.10. Others

    14.4. Market Value  Forecast By Distribution Channel, 2018–2030

        14.4.1. Hospital Pharmacies

        14.4.2. Drugstores

        14.4.3. Others

    14.5. Market Value  Forecast By Age Group, 2018–2030

        14.5.1. Pediatrics

        14.5.2. Adolescents

        14.5.3. Adults

        14.5.4. Geriatrics

    14.6. Market Value  Forecast By Country, 2018–2030

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Vaccine

        14.7.2. By Product

        14.7.3. By Distribution Channel

        14.7.4. By Age Group

        14.7.5. By Country

15. Middle East & Africa Human Vaccine Market Analysis and Forecast

    15.1. Introduction

    15.2. Market Value  Forecast By Vaccine, 2018–2030

        15.2.1. Conjugate

        15.2.2. Recombinant

        15.2.3. Inactivated

        15.2.4. Combination

        15.2.5. Attenuated

        15.2.6. Others

    15.3. Market Value  Forecast By Product, 2018–2030

        15.3.1. Pneumococcal

        15.3.2. Influenza

        15.3.3. Hepatitis

        15.3.4. HPV

        15.3.5. Meningococcal

        15.3.6. Rotavirus

        15.3.7. Measles and Rubella

        15.3.8. Typhoid

        15.3.9. Combination

        15.3.10. Others

    15.4. Market Value  Forecast By Distribution Channel, 2018–2030

        15.4.1. Hospital Pharmacies

        15.4.2. Drugstores

        15.4.3. Others

    15.5. Market Value  Forecast By Age Group, 2018–2030

        15.5.1. Pediatrics

        15.5.2. Adolescents

        15.5.3. Adults

        15.5.4. Geriatrics

    15.6. Market Value  Forecast By Country, 2018–2030

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis

        15.7.1. By Vaccine

        15.7.2. By Product

        15.7.3. By Distribution Channel

        15.7.4. By Age Group

        15.7.5. By Country

16. Competition Landscape

    16.1. Market Share Analysis By Company (2019)

    16.2. Company Profiles

        16.2.1. AstraZeneca plc

            16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.1.2. Growth Strategies

            16.2.1.3. SWOT Analysis

        16.2.2. Bavarian Nordic

            16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2.2. Growth Strategies

            16.2.2.3. SWOT Analysis

        16.2.3. Bharat Biotech

            16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.3.2. Growth Strategies

            16.2.3.3. SWOT Analysis

        16.2.4. CSL Limited

            16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.4.2. Growth Strategies

            16.2.4.3. SWOT Analysis

        16.2.5. Emergent BioSolutions, Inc.

            16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.5.2. Growth Strategies

            16.2.5.3. SWOT Analysis

        16.2.6. GlaxoSmithKline plc.

            16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.6.2. Growth Strategies

            16.2.6.3. SWOT Analysis

        16.2.7. Johnson & Johnson

            16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.7.2. Growth Strategies

            16.2.7.3. SWOT Analysis

        16.2.8. Merck & Co, Inc.

            16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.8.2. Growth Strategies

            16.2.8.3. SWOT Analysis

        16.2.9. Mymetics

            16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.9.2. Growth Strategies

            16.2.9.3. SWOT Analysis

        16.2.10. Novartis AG

            16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.10.2. Growth Strategies

            16.2.10.3. SWOT Analysis

        16.2.11. Pfizer, Inc.

            16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.11.2. Growth Strategies

            16.2.11.3. SWOT Analysis

        16.2.12. Sanofi S.A.

            16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.12.2. Growth Strategies

            16.2.12.3. SWOT Analysis

        16.2.13. Shenzhen Kangtai Biological Products Co., Ltd.

            16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.13.2. Growth Strategies

            16.2.13.3. SWOT Analysis

        16.2.14. Takeda Pharmaceutical Company Limited

            16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.14.2. Growth Strategies

            16.2.14.3. SWOT Analysis

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers